IDEXX director sells 2,203 shares at $532

Q: What did IDXX director Lawrence D. Kingsley report in this Form 4?

He reported exercising a non-qualified stock option for 2,203 shares of IDEXX common stock at $114.17 per share on September 4, 2026, and selling all 2,203 shares the same day at a weighted average price of $532.0826 per share.

Q: How many IDEXX (IDXX) shares did the director sell and at what price?

Lawrence D. Kingsley sold 2,203 shares of IDEXX common stock at a weighted average price of $532.0826 per share, with individual sale prices ranging from $531.88 to $532.14 per share.

Q: Was a Rule 10b5-1 trading plan used for this IDXX Form 4 transaction?

No. The filing does not indicate that the transactions reported by Lawrence D. Kingsley on September 4, 2026, were made under a Rule 10b5-1 trading plan.

IDEXX Laboratories, Inc. (IDXX) director Lawrence D. Kingsley reported an option exercise and share sale on September 4, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

IDEXX Laboratories, Inc. (IDXX) director Lawrence D. Kingsley reported an option exercise and share sale on September 4, 2026. He exercised a non-qualified stock option for 2,203 shares of common stock at an exercise price of $114.17 per share and sold all 2,203 shares at a weighted average price of $532.0826 per share, with sale prices ranging from $531.88 to $532.14. The option, which vested in one installment on May 3, 2017, now has no remaining derivative shares reported after the exercise, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Exercise and Sale: 2,203 shares ($921K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Kingsley Lawrence D

Role Director

Sold 2,203 shs ($1.17M)

Approx. gross sale proceeds $1.17M

Approx. exercise cost $252K

Approx. pre-tax spread $921K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right-to-buy) ^{F3, F2}	2,203	--	--
Exercise	Common Stock	2,203	$114.17	$252K
Sale	Common Stock ^F1	2,203	$532.0826	$1.17M

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 0 contracts (Direct); Common Stock — 9,568 shares (Direct)

Footnotes (3)

F1. Represents the weighted average price of the shares sold ranging from a low of $531.88 to a high of $532.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2017.
F3. Not applicable.

Key Figures

Options exercised: 2,203 shares Option exercise price: $114.17 per share Shares sold: 2,203 shares +4 more

7 metrics

Options exercised 2,203 shares Non-qualified stock option for IDEXX common stock exercised on September 4, 2026

Option exercise price $114.17 per share Exercise price of the non-qualified stock option underlying 2,203 shares

Shares sold 2,203 shares Common stock sold on September 4, 2026, following option exercise

Weighted average sale price $532.0826 per share Weighted average price of 2,203 IDEXX shares sold

Sale price range $531.88–$532.14 per share Range of prices for the shares sold on September 4, 2026

Option expiration date November 30, 2026 Expiration date of the reported non-qualified stock option

Remaining derivative shares 0 shares Non-qualified stock option position after exercising 2,203 options

Key Terms

Non-Qualified Stock Option (right-to-buy), weighted average price, common stock

3 terms

Non-Qualified Stock Option (right-to-buy) financial

"Non-Qualified Stock Option (right-to-buy)"

weighted average price financial

"Represents the weighted average price of the shares sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

common stock financial

"common stock that vested in one installment on May 3, 2017"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDXX director Lawrence D. Kingsley report in this Form 4?

He reported exercising a non-qualified stock option for 2,203 shares of IDEXX common stock at $114.17 per share on September 4, 2026, and selling all 2,203 shares the same day at a weighted average price of $532.0826 per share.

How many IDEXX (IDXX) shares did the director sell and at what price?

Lawrence D. Kingsley sold 2,203 shares of IDEXX common stock at a weighted average price of $532.0826 per share, with individual sale prices ranging from $531.88 to $532.14 per share.

What was the exercise price of the option in the IDXX Form 4?

The non-qualified stock option exercised by Lawrence D. Kingsley had an exercise price of $114.17 per share for 2,203 underlying shares of IDEXX common stock.

Were any IDEXX (IDXX) derivative securities left after this Form 4 transaction?

For the reported non-qualified stock option, the filing shows 0 derivative shares remaining after exercising 2,203 options into common stock on September 4, 2026.

Was a Rule 10b5-1 trading plan used for this IDXX Form 4 transaction?

No. The filing does not indicate that the transactions reported by Lawrence D. Kingsley on September 4, 2026, were made under a Rule 10b5-1 trading plan.

When did the IDEXX option reported in this Form 4 originally vest and when does it expire?

The filing states the option to buy IDEXX common stock vested in one installment on May 3, 2017 and carried an expiration date of November 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/09/2026 - 05:00 PM EDT Accepted by SEC EDGAR 09/09/2026 - 05:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kingsley Lawrence D

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

MAINE

04092

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/04/2026		M		2,203	A	$114.17	11,771	D
Common Stock	09/04/2026		S		2,203	D	$532.0826⁽¹⁾	9,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$114.17	09/04/2026		M			2,203	⁽²⁾	11/30/2026	Common Stock	2,203	⁽³⁾	0	D

Explanation of Responses:

1. Represents the weighted average price of the shares sold ranging from a low of $531.88 to a high of $532.14 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

2. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2017.

3. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Lawrence D. Kingsley	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR